The Biodistribution of N-{4-[3'-[F-18] Fluoroethylphenyl)Amino]-6-quinazolinyl}-Acrylamide ([F-F18]FEQA) in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and in Healthy Subjects: A Pilot Study
OBJECTIVES:
- Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV
non-small cell lung cancer (NSCLC) and in healthy participants.
- Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron
emission tomography in patients with stage III or IV NSCLC.
OUTLINE: This is a pilot study.
Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body
dynamic scans comprising positron emission tomography.
Blood is collected during and after imaging to measure radioactivity.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Biodistribution of fluorine F 18 FEQA
No
Johannes Czernin, MD
Study Chair
Jonsson Comprehensive Cancer Center
United States: Institutional Review Board
CDR0000529363
NCT00444223
May 2004
Name | Location |
---|---|
Jonsson Comprehensive Cancer Center at UCLA | Los Angeles, California 90095-1781 |